Showing 15 posts of 48 posts found.


Bayer’s Jivi approved in Europe for previously treated haemophilia A

November 28, 2018
Research and Development, Sales and Marketing Bayer, Jivi, haemophilia, pharma

Bayer has revealed that its recombinant Factor VIII (rFVIII) replacement therapy Jivi, also known as BAY94-9027, has received approval from …


FDA expands indication of Roche’s Hemlibra in haemophilia

October 5, 2018
Medical Communications, Sales and Marketing Hemlibra, Roche, haemophilia, pharma

The FDA has chosen to expand the label of Roche’s Hemlibra (emicizumab-kxwh), approving it for routine prophylaxis to prevent the …

Bayer to cut 227 positions in California to drive efficiency in haemophilia

October 4, 2018
Manufacturing and Production Bayer, haemophilia, pharma

Bayer has announced its intention to axe 227 employees at a manufacturing site in California as part of a push …


Strong efficacy but serious side-effects with Spark’s haemophilia drug drop shares by 30%

August 8, 2018
Research and Development Spark Therapeutics, haemophilia, pharma

Spark Therapeutics has been left reeling after it revealed new data on its haemophilia A treatment, which, while promising in …


Roche’s Hemlibra stakes claim to be haemophilia market leader

May 21, 2018
Research and Development, Sales and Marketing Hemlibra, Roche, Shire, biotech, drugs, haemophilia, pharma, pharmaceutical

Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only …


Five deaths linked to Roche’s haemophilia drug Hemlibra

March 28, 2018
Research and Development Genentech, Hemlibra, Roche, haemophilia, pharma

Roche has been rocked by the revelation that there have been five patient deaths linked to the use of its …

Europe approves first therapy for haemophilia A with inhibitors in over 20 years

March 1, 2018
Research and Development Europe, European Commission, Hemlibra, Roche, haemophilia, pharma

Roche has revealed that its bispecific factor IXa- and factor X-directed antibody Hemlibra (emicizumab) has been approved by the European …


Shire scores European approval for Adynovi in haemophilia A

January 15, 2018
Sales and Marketing Adynovi, Europe, European Commission, Shire, haemophilia, haemophilia a, pharma

Shire has revealed that the European Commission has approved Adynovi (antihaemophilic factor (recombinant), PEGylated) for on-demand and prophylactic use in …


Top Ten most popular articles on Pharmafile.com this week

December 15, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ionis, Sanofi, Teva, haemophilia, pharma, top ten

Just 10 days away from Christmas, and big news is still flowing in the industry. Sanofi remains embroiled in scandal …


‘Mind-blowing’ gene therapy could herald a cure for haemophilia, study shows

December 14, 2017
Research and Development haemophilia, pharma

A team of clinical researchers at Barts Health NHS Trust and Queen Mary University of London have reported that a …


Roche’s haemophilia A drug shows meaningful bleed control in P3

December 7, 2017
Research and Development Roche, haemophilia, pharma

Roche has unveiled new Phase 3 data for its haemophilia A treatment Helimbra (emicizumab) in patients over 12 years of …


Contaminated blood inquiry to probe thousands of deaths

July 12, 2017
Medical Communications, Research and Development HCV, HIV, biotech, drugs, haemophilia, pharma, pharmaceutical

UK Government has announced that it will launch an inquiry to discover how 4,670 people were given blood infected by …


Shire and Roche haemophilia spat spills into court

July 10, 2017
Sales and Marketing Roche, Shire, haemophilia

Roche released new scientific data at a conference in Berlin regarding its developmental drug in haemophilia, emicizumab, and Shire chose …


Roche haemophilia therapy cuts bleed rate by 87%

June 26, 2017
Research and Development, Sales and Marketing Roche, haemophilia

Roche has revealed new data on its investigational haemophilia therapy ACE910 (emicizumab) which shows an 87% reduction in bleed rate …


‘World Hemophilia Day’ marked by release of data

April 20, 2017
Medical Communications, Research and Development Roche, Shire, haemophilia

‘World Hemophilia Day’ occurred on 17 April and the day was marked by the release of data from two companies …

Latest content